The latest version of the artificial intelligence (AI) model, AlphaFold 3, has been touted as a game-changer for drug discovery, because it can model the interaction of proteins with other molecules, including drugs. But a lack of examples of these interactions in the data underpinning AlphaFold ' hundreds of thousands of publicly available protein structures ' is holding the tool back for the applications that drug companies are most interested in, say scientists. A consortium of leading pharmaceutical companies announced plans today to make their own AlphaFold-3-inspired AI model using thousands of protein structures that are currently secreted away in company vaults. This is in addition to the more than 200,000 protein structures freely available in the Protein Data Bank (PDB). 'The data that's missing from the PDB is exactly the data that's present in our internal data,' says John Karanicolas, head of computational drug discovery at the pharma company AbbVie in Chicago,...
learn more
